Celyad SA Skyrocketed

Celyad SA (CYAD:NASDAQ) shot up at $2.45, representing a gain of 40.8%. On Mon, Aug 01, 2022, CYAD:NASDAQ touched a New 2-Week High of $2.45. The stock appeared on our News Catalysts scanner on Mon, Aug 01, 2022 at 09:41 AM in the 'BIOTECH' category. From Mon, Jul 18, 2022, the stock recorded 50.00% Up Days and 22.22% Green Days
About Celyad SA (CYAD:NASDAQ)
Celyad SA is a biopharmaceutical company. The company is engaged in stem cell-based therapies for the treatment of cardiovascular diseases. It is developing therapeutic therapies based on two distinct technology platforms in cardiology and oncology.
Top 10 Gainers:
- Virax Biolabs Group Limited (VRAX:NASDAQ), 119.44%
- Ontrak Inc. (OTRK:NASDAQ), 107.69%
- Revlon, Inc. (REV:NYSE), 89.93%
- AMTD Digital Inc. American Depositary Shares (every five of which represent two Class A) (HKD:NYSE), 85.38%
- Mediaco Holding Inc. (MDIA:NASDAQ), 60.87%
- Nanobiotix S.A. (NBTX:NASDAQ), 46.98%
- Celyad SA (CYAD:NASDAQ), 40.8%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 38%
- TherapeuticsMD, Inc. (TXMD:NASDAQ), 36.6%
- MAIA Biotechnology Inc. (MAIA:NYSEMKT), 34.48%